Advertisement

Radical Radiotherapy for Prostate Cancer

  • Mererid Evans
  • Malcolm D. Mason

Abstract

The incidence of prostate cancer is rising worldwide due to the ageing of the population and the increasing availability of prostate-specific antigen (PSA) screening. Prostate-specific antigen testing has led specifically to an increase in the proportion of patients diagnosed with early-stage (localized) prostate cancer. Radical radiotherapy is one of the curative treatment options for localized prostate cancer and it also has a role to play in locally advanced and even metastatic disease. This chapter reviews the relative merits of radiotherapy in comparison to the other management options for early prostate cancer and summarizes the staggering technological advances that have occurred in prostate radiotherapy over the last decade.

Keywords

Prostate Cancer Radical Prostatectomy Radiat Oncol Biol Phys Radiation Therapy Oncology Group Radical Radiotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomised trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781–789.PubMedCrossRefGoogle Scholar
  2. 2.
    Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982;128:502–504.PubMedGoogle Scholar
  3. 3.
    D’Amico AV, Whittington R, Malcowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localised prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281–286.PubMedCrossRefGoogle Scholar
  4. 4.
    Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localised prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002;20:3376–3385.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial; a randomised trial comparing radical prostatectomy versus expectant management for the treatment of clinically localised prostate cancer. J Urol 1994;152:1910–1914.PubMedGoogle Scholar
  6. 6.
    Madalinska JB, Essink-Bot M-L, de Koning HJ, et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localised prostate cancer. J Clin Oncol 2001;19:1619–1628.PubMedGoogle Scholar
  7. 7.
    Seddon B, Bidmead M, Wilson J, et al. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial. Radiother Oncol 2000;56:73–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095–1101.PubMedCrossRefGoogle Scholar
  9. 9.
    Livsey JE, Cowan RA, Wylie JP, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 2003;57:1254–1259.PubMedCrossRefGoogle Scholar
  10. 10.
    Lukka H, Hayter C, Warde P, et al. A randomised trial comparing two fractionation schedules for patients with localised prostate cancer. Int J Radiat Oncol Biol Phys 2003;57(suppl).Google Scholar
  11. 11.
    Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localised prostate cancer. J Urol 2001;166:876–881.PubMedCrossRefGoogle Scholar
  12. 12.
    Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003;57:915–928.PubMedCrossRefGoogle Scholar
  13. 13.
    Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267–272.PubMedCrossRefGoogle Scholar
  14. 14.
    Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson Phase III randomised trial. Int J Radiat Oncol Biol Phys 2002;53:1097–1105.PubMedCrossRefGoogle Scholar
  15. 15.
    Ryu JK, Winter K, Michalski JM. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2Gy). Int J Radiat Oncol Biol Phys 2002;54:1036–1046.PubMedCrossRefGoogle Scholar
  16. 16.
    Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111–1116.PubMedCrossRefGoogle Scholar
  17. 17.
    Kupelian PA, Reddy CA, Carlson TP, et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70Gy at 2.5Gy/fraction) for localised prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:904–912.PubMedCrossRefGoogle Scholar
  18. 18.
    Roach M III, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003;21:1904–1911.PubMedCrossRefGoogle Scholar
  19. 19.
    Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimised intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:649–656.PubMedCrossRefGoogle Scholar
  20. 20.
    Merrick GS, Butler WM, Galbreath RW, et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001;51:41–48.PubMedCrossRefGoogle Scholar
  21. 21.
    Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:31–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavourable prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:316–327.PubMedCrossRefGoogle Scholar
  23. 23.
    Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate brachytherapy as monotherapy for localised prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys 2003;56:213–220.PubMedCrossRefGoogle Scholar
  24. 24.
    Zelefsky MJ, Leibel SA, Burman CM, et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994;29:755–761.PubMedGoogle Scholar
  25. 25.
    Henderson A, Langley SEM, Laing RW. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol 2003;15:318–321.CrossRefGoogle Scholar
  26. 26.
    Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavourable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013–1021.PubMedGoogle Scholar
  27. 27.
    Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavourable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937–946.PubMedCrossRefGoogle Scholar
  28. 28.
    Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300.PubMedCrossRefGoogle Scholar
  29. 29.
    Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103–108.PubMedCrossRefGoogle Scholar
  30. 30.
    Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243–1252.PubMedCrossRefGoogle Scholar
  31. 31.
    Hanks GE, Lu J, Machtay M, et al. RTOG protocol 92-02: a phase III trial of the use of long-term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc Annu Meet Am Soc Clin Oncol 2000;19:1284.Google Scholar
  32. 32.
    Roach M III, Lu JD, Lawton C, et al. A phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): preliminary analysis of RTOG 9413. Int J Radiat Oncol Biol Phys 2001;51(suppl 1).Google Scholar
  33. 33.
    Roach M III, Lu J, Pilepich MV, et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47:617–627.CrossRefGoogle Scholar
  34. 34.
    Fellows GJ, Clark PB, Beynon LL, et al. Treatment of advanced localised prostatic cancer by orchidectomy, radiotherapy or combined treatment. A Medical Research Council Study. Urological Cancer Working Party-Subgroup on Prostatic Cancer. Br J Urol 1992;70:304–309.PubMedGoogle Scholar
  35. 35.
    Catton C, Gospodarowicz M, Warde P, et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 2001;59:51–60.PubMedCrossRefGoogle Scholar
  36. 36.
    Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–1597.PubMedCrossRefGoogle Scholar
  37. 37.
    Parker C, Warde P, Catton C. Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother Oncol 2001;61:107–116.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2007

Authors and Affiliations

  • Mererid Evans
    • 1
  • Malcolm D. Mason
    • 1
  1. 1.Section of Clinical Oncology and Palliative MedicineUniversity of Wales College of Medicine Velindre HospitalCardiffUK

Personalised recommendations